Introduction: Sustained-release corticosteroid implants are injected into the vitreous cavity using preloaded pens. The fluocinolone (FAc) implant is approximately half the size of the dexamethasone implant (Dex-I). It is simply introduced in the vitreous base rather than propelled into the vitreous cavity as is Dex-I. Verification of its positioning after injection is thus difficult by indirect ophthalmoscopy. The goal of our study is to compare the performance of available clinical and imaging tools to confirm the presence of the FAc in the vitreous cavity following injection.
Methods: Twelve eyes of 12 consecutive patients were included in a retrospective, single-center, observational study carried out at the Bordeaux University Hospital, France. All patients were injected with the FAc after pupil dilation, and presence of the implant was immediately checked by indirect biomicroscopy, wide-field retinography (Clarus®, Carl-Zeiss-Meditec, Dublin, CA, USA) and ultra-wide-field retinography (California®, Optos, Edinburgh, United-Kingdom). Seven days later, a B-mode ultrasonography (10MHz, AVISO, Quantel-medical, France) and an UBM ultrasonography (50MHz, AVISO, Quantel-medical, France) were performed.
Results: Indirect biomicroscopy and wide-field retinography detected 4/12 implants (33.3%). Ultra-wide-field retinophotography detected 6/12 implants (50%). All the implants seen using indirect biomicroscopy and wide-field retinography were also visualized with ultra-wide-field. B-mode ultrasonography showed 5/12 implants (41.6%) and UBM 9/12 implants (75%). Finally, one implant dislocated into the anterior chamber and was seen in the iridocorneal angle on gonioscopy.
Conclusion: Objective confirmation of the proper positioning of the FAc implant in the vitreous cavity is mandatory. If both indirect ophthalmoscopy and anterior examination fail to detect it, ultra-wide field retinography along with UBM ultrasonography, if necessary, appear to be the two best imaging modalities to use.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jfo.2022.09.034 | DOI Listing |
Eur J Pharmacol
January 2025
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital. Electronic address:
Retinal vein occlusion (RVO) has become the second most common retinal vascular disease after diabetic retinopathy. Existing therapeutic approaches, including intravitreal injection of antivascular endothelial growth factors (anti-VEGFs) and/or glucocorticoids and laser therapy, primarily address secondary macular edema and neovascularisation. However, these strategies do not address the underlying cause of the disease and may have harmful side effects.
View Article and Find Full Text PDFRetina
January 2025
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Purpose: To present a novel bended-needle drainage system in vitreous cavity lavage (VCL) for postoperative vitreous cavity hemorrhage (POVCH).
Methods: This retrospective case series include all patients with POVCH who received VCL with the bended-needle drainage system at ophthalmology department of Peking Union Medical College Hospital from January 2022 to May 2024. Patients adopted a supine position that allows preparation and draping.
Int J Retina Vitreous
January 2025
Department of Ophthalmology and Visual Sciences, Federal University of São Paulo (UNIFESP), Rua Botucatu, 822, Vila Clementino, São Paulo/SP, 04023-062, Brazil.
Background: Ozurdex® (Allergan®, AbbVie Company, North Chicago, Illinois, EUA), is composed of 0.7 mg of dexamethasone, fused in a solid biodegradable PLGA polymer, whose degradation occurs naturally in the vitreous cavity, usually in six months after its application.
Methods: In this study, we included patients aged ≥ 18 years with one or two eyes who had an indication for Ozurdex implants.
Am J Ophthalmol
January 2025
Raghudeep Eye Hospital, Laden Cataract and IOL research centre, Ahmedabad, India 380052.
Purpose: To evaluate demographic profile, risk factors and outcomes following intraocular lens (IOL) exchange surgery for late decentration of IOLs in the dead bag syndrome DESIGN: Prospective, interventional case series PARTICIPANTS: 46 eyes (43 patients) with late decentration/dislocation of IOLs and spontaneous posterior capsule rupture in a clear and relatively intact capsular bag. None of the eyes had significant zonular weakness.
Methods: Study conducted at Raghudeep Eye Hospital, India.
Cureus
December 2024
Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, JPN.
Objectives This study aimed to identify the etiology and the direction of dislocation of the natural crystalline lens or intraocular lens (IOL) in IOL intrascleral fixation surgery and to determine the change in intraocular pressure (IOP) after surgery. Methods We retrospectively investigated the diagnosis, direction of lens and IOL dislocation, and IOP before and after surgery (preoperatively and one day, one week, and one month postoperatively) in 236 eyes from 228 patients who underwent IOL intrascleral fixation at Chiba University Hospital between February 2015 and September 2020. Results IOL intrascleral fixation was performed in 48 (20.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!